Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Brought to you by

Medgenics completes its IPO on the NYSE

14 Nov 2011

Executive Summary

Medgenics Inc. (combination therapeutics/devices for sustained treatment of chronic diseases) has netted $10.9mm through its initial public offering on the New York Stock Exchange. After filing in November 2010, the company announced plans two months ago to sell 2.5mm shares for between $4-7 each. It finalized the offering by selling 2.62mm shares (including the overallotment) at $4.54, with five-year warrants to purchase another 2.8mm shares at $6 apiece.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By